Inovio Pharmaceuticals Inc (NASDAQ:INO)‘s stock had its “buy” rating reissued by stock analysts at Stifel Nicolaus in a research report issued on Thursday. They currently have a $11.00 target price on the biopharmaceutical company’s stock. Stifel Nicolaus’ target price indicates a potential upside of 39.59% from the stock’s current price.

A number of other analysts have also issued reports on the company. Maxim Group lifted their price target on Inovio Pharmaceuticals from $10.00 to $12.00 and gave the stock a “buy” rating in a research note on Wednesday. Aegis reaffirmed a “buy” rating and issued a $11.00 price target on shares of Inovio Pharmaceuticals in a research note on Wednesday, May 17th. Zacks Investment Research raised Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, May 15th. HC Wainwright set a $13.00 price target on Inovio Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, May 11th. Finally, Nomura reaffirmed a “buy” rating and issued a $40.00 price target on shares of Inovio Pharmaceuticals in a research note on Monday, May 1st. Four research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $19.16.

Analyst Recommendations for Inovio Pharmaceuticals (NASDAQ:INO)

Inovio Pharmaceuticals (NASDAQ:INO) traded down 1.38% during mid-day trading on Thursday, reaching $7.88. The company had a trading volume of 1,631,705 shares. The stock’s market capitalization is $588.06 million. The stock has a 50 day moving average of $6.68 and a 200 day moving average of $6.81. Inovio Pharmaceuticals has a 52 week low of $5.83 and a 52 week high of $11.62.

Inovio Pharmaceuticals (NASDAQ:INO) last issued its quarterly earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.31). The firm had revenue of $10.40 million for the quarter, compared to analyst estimates of $5.83 million. Inovio Pharmaceuticals had a negative return on equity of 39.93% and a negative net margin of 199.99%. The business’s revenue was up 28.4% on a year-over-year basis. During the same period in the previous year, the company posted ($0.11) earnings per share. Analysts anticipate that Inovio Pharmaceuticals will post ($1.10) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Inovio Pharmaceuticals Inc (INO) Earns Buy Rating from Stifel Nicolaus” was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was copied illegally and republished in violation of United States & international copyright & trademark law. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/05/27/inovio-pharmaceuticals-inc-ino-earns-buy-rating-from-stifel-nicolaus.html.

In related news, Director Morton Collins acquired 21,300 shares of the stock in a transaction on Monday, March 27th. The shares were bought at an average price of $6.25 per share, with a total value of $133,125.00. Following the completion of the purchase, the director now owns 142,291 shares of the company’s stock, valued at approximately $889,318.75. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director David B. Weiner sold 8,000 shares of the business’s stock in a transaction on Thursday, May 25th. The stock was sold at an average price of $8.00, for a total value of $64,000.00. Following the transaction, the director now directly owns 740,956 shares in the company, valued at approximately $5,927,648. The disclosure for this sale can be found here. Insiders own 9.90% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in Inovio Pharmaceuticals by 7.9% in the first quarter. Vanguard Group Inc. now owns 3,098,055 shares of the biopharmaceutical company’s stock worth $20,510,000 after buying an additional 226,861 shares during the period. Russell Investments Group Ltd. acquired a new stake in Inovio Pharmaceuticals during the fourth quarter worth approximately $559,000. Credit Suisse AG increased its stake in Inovio Pharmaceuticals by 108.6% in the first quarter. Credit Suisse AG now owns 132,688 shares of the biopharmaceutical company’s stock worth $879,000 after buying an additional 69,068 shares in the last quarter. Geode Capital Management LLC increased its stake in Inovio Pharmaceuticals by 12.5% in the first quarter. Geode Capital Management LLC now owns 560,164 shares of the biopharmaceutical company’s stock worth $3,708,000 after buying an additional 62,045 shares in the last quarter. Finally, New York State Common Retirement Fund increased its stake in Inovio Pharmaceuticals by 32.6% in the third quarter. New York State Common Retirement Fund now owns 230,458 shares of the biopharmaceutical company’s stock worth $2,148,000 after buying an additional 56,631 shares in the last quarter. 28.72% of the stock is currently owned by institutional investors.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

12 Month Chart for NASDAQ:INO

Receive News & Ratings for Inovio Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.